BioPharma Dive November 12, 2024
The deal with Vesalius Therapeutics is the latest pharma validation for Flagship, which has in recent years allied with Pfizer and Novo Nordisk.
Flagship Pioneering startup Vesalius Therapeutics has signed a deal with GSK, the companies announced Tuesday, for the British pharma to use its technology to find medicines for neurodegenerative disorders.
Under the terms of the deal, GSK will hand Vesalius $80 million in upfront and equity payments. Vesalius will lead the drug discovery process to identify drugs for Parkinson’s disease and a second, unnamed neurodegenerative condition. The agreement also gives GSK development and commercialization rights to a preclinical small molecule drug for Parkinson’s, as well as an option to advance other programs.
If successful, Vesalius could stand to...
Today's Sponsors
Today's Sponsor